



ANALYSIS GROUP

Raising the standard in health care and epidemiology research

Analysis Group Posters and Presentations

ISPOR EUROPE 2026 | 8-11 NOVEMBER | VIENNA, AUSTRIA

Analysis Group's health care professionals have extensive experience helping clients quantify product value in a dynamic and rapidly changing marketplace.

This year, we are pleased to present an educational symposium and five research posters. Please find details below.

If time permits, please say hello to our team at Booth #1129.

All posters will be on display in the Exhibit Hall during their allotted poster session. To view the corresponding abstract and author list for a poster, please click on the **Poster Code** or **Title** below.

Poster Code	Title	Poster Session
<u>HSD9</u>	Current Treatment Patterns in Non-Metastatic Melanoma in the Modern Treatment Era: A Surveillance, Epidemiology, and End Results (SEER)-Medicare Analysis	Poster Session 1 Monday, 9 November 10:30–13:30
<u>EE360</u>	Clinical and Economic Burden of Hospitalization for Exacerbation or Crisis Among Patients with Generalized Myasthenia Gravis in the United States	Poster Session 3 Tuesday, 10 November 10:30–13:30
<u>MSR143</u>	Longitudinal Adherence Patterns of Asciminib versus Other Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Group-Based Trajectory Analysis	Poster Session 3 Tuesday, 10 November 10:30–13:30
<u>CO182</u>	Effectiveness of Pneumococcal Conjugate Vaccines in Preventing Pneumonia in Children — A Targeted Literature Review	Poster Session 4 Tuesday, 10 November 16:00–19:00
<u>EE708</u>	Clinical and Economic Outcomes of Whole-Body MRI Screening: A US Employer Perspective	Poster Session 5 Wednesday, 11 November 09:00–11:30

ISPOR Europe 2026 Analysis Group Presentation

EDUCATIONAL SYMPOSIUM

Monday, 9 November | 12:15–13:15

Advancing Evidence-Based Medicine with Generative AI

Generative AI (GenAI) is increasingly being explored as a tool for analyzing multi-source and multi-modal data to derive comprehensive insights into the progression of complex diseases, evaluate interventions, and support evidence-based decision making.

This symposium will explore the frontiers of GenAI in evidence-based medicine and precision health, highlighting methodological advances and practical applications. Presenters will demonstrate how heterogeneous data sources can be enriched and integrated to generate context-specific yet broadly relevant insights and support precision health research. The symposium will showcase the use of GenAI, including digital twin methodologies to predict the long-term progression of obesity and chronic cardiometabolic diseases and assess treatment impacts over time. One such model, DECODE, has demonstrated strong performance in capturing the interconnected nature of cardiometabolic conditions, predicting disease progression, and evaluating the long-term clinical and economic impact of interventions.

The presenters will illustrate how GenAI and digital twins can support a continuum of evidence generation, from modeling disease progression and long-term treatment effects to individualized prediction and enhanced clinical trial design, while strengthening how evidence is generated and interpreted for health care decision making. Initiatives such as the Consortium for Obesity & Cardiometabolic Research & Evidence (CORE) further advance this effort, bringing together academic and industry leaders to bolster the scientific rigor and policy relevance of precision health research and facilitate its real-world translation.

Presenters: [Jimmy Royer](#), Ph.D.; Principal, Analysis Group
Maxime Leroux, M.Sc.; Founder and Principal Consultant, DMined Consulting Services

Moderator: [Eric Q. Wu](#), Ph.D.; Managing Principal, Analysis Group